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Summary: The ability of two S,S'-(alkane-l,(o-diyl) bisisothiouronium dibromides, three N,N'-(alkane-l,(u-diyl) bis
guanidinium dinitrates and Ν,Ν'-bis (3-guanidinopropyl)piperazine dinitrate to inhibit constitutive (i. e. endothelial
and neuronal forms) and inducible forms of nitric oxide synthases has been evaluated in vivo. These compounds,
synthesized by two of us (J. C. L. and C. S.), have been tested in vivo; they were administered simultaneously with
an irritant (carrageenan λ) into the pleural cavity. The amount of nitrites collected 0.5 and 7 hours after this injection
can be considered as an indicator of nitric oxide (NO) production. According to previous data, the first harvesting
time can be related to activation of constitutive NO synthases and the second to activation of inducible NO syn-
thases.
These substances significantly inhibited nitrite production as did 2-methyl-2-thiopseudourea sulphate, previously
described as a potent inhibitor of NO synthases and considered as the reference compound.
The inhibiting effect varied according to the chemical structure of the compounds. Results were significantly
different from controls at 0.5 h only with the S,S'-(octane-l,8-diyl) bisisothiouronium dibromide and the S,S'-
(nonane-l,9-diyl) bisisothiouronium dibromide at the highest concentration, N,N'-(heptane-l,7-diyl) bisguanidinium
dinitrate and Ν,Ν'-bis (S-guanidinopropyl)piperazine dinitrate. At 7 h, all the results were significantly different
from controls, with a major effect observed with N,N'-(heptane-l,7-diyl) bisguanidinium dinitrate.
The most active substances exerted similar effects to the reference substance.
Introduction
Nitric oxide (NO), a small membrane permeable gas, is
enzymatically formed from a terminal guanidino nitro-
gen of L-arginine (1) by a family of three distinct NO
synthase isoenzymes (2) and plays several physiological
roles (3). In this way, enhanced formation of NO
following the induction of a distinct isoform of inducible
NO synthase has been implicated in the pathogenesis of
a number of inflammatory reactions and, consequently,
inhibitors of inducible NO synthases may have thera-
peutic potential (4).
L-arginine
NO synthase inhibitors -
L-citrulline
As NO is derived from the guanidino group of L-argi-
nine (fig. 1, a), several strong inhibitors of NO synthases
have been obtained by addition of a functional group on
the molecule or by substitution of one of the guanidino
nitrogens. In that way,
i) N(co)-monomethyl-L-arginine (fig. l,b), a non-selec-
tive NO synthase inhibitor,
ii) N(co) nitro-L-arginine (fig. l,c), an active metabolite
of N(a>)-nitro-L-arginine methylester (fig. 1, d), which
is more lipophilic than the other arginine analogs and
therefore is able to penetrate the cell membrane, and fi-
nally
iii) N(co)-amino-L-arginine (fig. 1 e) have been synthe-
sized (5—7) as prototype arginine analogs. These NG-
substituted L-arginine analogs have been extensively
used to inhibit NO synthase activity in vitro and in vivo
(5), but their specificity is limited (8).
In the guanidino group, the isosteric replacement of the
terminal imine function by a sulphur atom gave rise to
a new class of inhibitors including L-thiocitrulline (9)
(fig. 1, f), while the replacement of the NH2 function by
a S-alkyl group led to compounds such as S-methyl (fig.
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l,g) or S-ethyl-L-isothiocitrulline (fig. l,h). The latter
compounds are shown to be potent, reversible and slow-
binding inhibitors of all NO synthases but are, respec-
tively, 10- and 50-fold more potent inhibitors of neuro-
nal than endothelial NO synthases (10).
It appears that the guanidine moiety of Ζ,-arginine -NH-
C(=NH)-NH2 is the pharmacophore group. This fact
prompted the study of anti-NO synthase properties of
non-amino acid based inhibitors (fig. 2) such as amino-
guanidine (fig. 2, a) containing a hydrazine moiety that
might confer selectivity for the inducible NO synthase
(11). The N,N'-l,3-diaminoguanidine compound (fig.
2,b), which appeared to be selective for inducible NO
synthase (12), seemed less potent than aminoguanidine.
The most potent inhibitors of inducible NO synthase
among the guanidino group seemed to be mercaptopro-
pyl and mercaptoethylguanidine (13) (fig. 2,c).
Among the N5N'-(alkane-l,o>-diyl) bis (guanidine) com-
pounds, arcaine (fig. 2, d), the 1,4-diguanidino-butane ex-
hibited a moderate inhibition of NO synthases (14).
In the -NH-C(=NH)-NH2 guanidine moiety the second-
ary amine isosteric replacement by a sulfur atom gave
rise to a new class of S-substituted isothiourea com-
pounds called the ITU group R-S-C(=NH)-NH2, (fig.
2, e) which appeared to be strong inhibitors of NO syn-
HOOC
\ /) (CH2)3 N H C
H3N V
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N H
thases (15—17). S-ethyl-isothiourea and S-isopropyl-
isothiourea seemed to be the most potent structures of
the straight chain, while extension of the side chain R
decreased the potency (n-propyl > i-butyl > «-butyl)
(15). Another isothiourea potent group was bis-isothio-
urea (fig. 2, f), in which sulphur atoms of two isothi-
ourea units were linked by a carbon chain, containing
eventually unsatured (hetero)cyclic rings. Some of these
bis isothioureas showed marked selectivity for the hu-
man inducible NO synthase when compared to constitu-
tive NO synthases. The bis-isothiourea, S,S'-(l,3-phe-
nylenebis(l,2-ethanediyl)bis-isothiourea (fig. 2,g) was
190-fold more selective for the inducible NO synthase
than for endothelial NO synthase (15).
Guanidine and isothiourea can be classified as deriva-
tives of amidine. The propionamidine compound (fig.
2, h) and longer chained amidines inhibited the inducible
NO synthase (18).
Here was examined the ability of some S,S'-(alkane-
Ι,ω-diyl) bisisothiouronium dibromides and N,N'-(al-
kane-l,co-diyl) bisguanidinium dinitrates and the newly
synthesized Ν,Ν'-bis (3-guanidinopropyl)piperazine
dinitrate to inhibit, in the rat, NO generation in the
course of an inflammatory reaction. Some of these
compounds (bisisothiouronium salts) have already been
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Fig. 1 Chemical structure of ί,-arginine based inhibitors of NO synthases.
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Fig. 2 Chemical structure of non-amino acid based inhibitors of NO synthases.
tested in vitro, but not in vivo (15). To our knowledge,
the bisguanidinium salts were already synthesized but
tested neither in vitro nor in vivo as NO synthase in-
hibitors.
We explored the potential selectivity of these agents
towards constitutive and inducible isoforms of NO syn-
thases in comparison to the activity of 2-methyl-2-thio-
pseudourea sulphate previously described as a potent
NO synthase inhibitor by SOwi/ζα« et al. (16) and consid-
ered as the reference compound.
Material and Methods
Chemicals
Two S,S'-(alkane-l,a)-diyl) bisisothiouronium dibromides have
been synthesized according to the method described by Garvey et
al. (15).
,
C— S— R— S— C
/ \
NH2
(CH2),(CH2),
Compound
I
Π
Three N,N'-(alkane-l,o)-diyl) bisguanidinium dinitrates were syn-
thesized according to the method described by Tesman et al. (19).
H2NX NH2 Compound
(CH2)6 ΙΠ(CH2)7 IV
V
Synthesis of Ν,Ν'-bis (2-guanidinopropyl) piperazine dinitrate
(compound VI)
C - NH - (CH.,)a -
 N N - (CH2)3 - N H — C
NH2
2NO3
4.02 g (0.02 mol) of 3,5-dimethylpyrazol-l-carboxamidine nitrate
were added to a solution of 2 g (0.01 mol) of 1,4 bis (3-aminopropyl)
piperazine in 50 ml of ethanol. The mixture was refluxed for 5 hours
and cooled. The white precipitates were collected by drying, washed
with 20 ml of acetonitrile and 50 ml diethylether to yield 3.7 g (90%
of theory) of the bis-guanidinium salt (ethanol) (m. p. = 218 °C).
Infrared spectroscopy (KBr): 3300, 3285, 3200, 2978, 2825, 2820,
(ΝΗί) cm-1.
H nuclear magnetic resonance d^ 7.43, 6.82 (m, 10 H, NHJ), 3.10,
2.35, 2.29, 1.62 (m, 20 H, (CH2)3, CH2 piperazine) ppm.
Elementary analysis for C12H3oN10O6 (Mr 410.41).
Calculated: C, 35.11%; H, 7.36%; N, 34.12%.
Found: C, 35.21%; H, 7.42%; N; 34.18%.
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Carrageenan λ was obtained from Pierrefitte Auby (Neuilly/Seine,
France) Hank's solution (without phenol red), N-(l-naphthyl)-ethy-
lenediamine, and sulphanilamide were purchased from Sigma
Chemical Co. (St. Louis, Mo, USA). Phosphoric acid was
purchased from Merck (Darmstadt, Germany) and 2 methyl-2-thio-
pseudourea sulphate was purchased from Aldrich (Steinheim, Ger-
many).
Animals and treatments
Male Sprague-Dawley rats weighing 180-200 g (Depre, Saint-
Doulchard, France) were used for all experiments (20). Protocols
were submitted and approved by the local ethics committee.
Pleurisy was induced by intrapleural injection of 0.1 ml of 10 g/1
carrageenan λ suspension in saline (21).
The methyl 2-thiopseudourea sulphate, bisisothiouronium and bis-
guanidinium salts (0.1 ml) were administered with the inflamma-
tory stimulus into the pleural cavity at concentrations varying from
5 X 10~6 to 10~4 mol/1.
Animals were euthanized with ether, and the right pleural cavity
was opened for pleural exudate collection at 30 min (t = 0.5 h) or
seven hours (t = 7 h). Samples were centrifuged at 500 g for 5 min,
and the supernatants were then centrifuged at 1000 g for 20 min in
order to remove exudate fibrin. Samples were then adjusted to a
final volume of 1 ml with Hank's solution and stored at -80 °C
until nitrite determination was carried out.
Nitrite determination in pleural exudate
Nitrite was measured in pleural exudates as an indicator of NO
formation (22). Aliquots of 0.1 ml were incubated in individual
wells of a 96-well plate, with 0.1 ml of Griess reagent (0.5 g/l N-
(l-naphthyl)-ethylenediamine and 5 g/1 sulphanilamide in phos-
phoric acid (50 g/1), at room temperature for 10 min. The absor-
bance was measured at 550 nm using a microplate reader (Dyna-
tech, MRX), in comparison with the incubating medium (Hank's
solution) without cells. Sodium nitrite was used to establish a ni-
trate standard curve.
Statistical analysis
The Mann-Whitney U test (in the computer program Statview II)
was carried out in each group between treated and nontreated rats.
Results were given as a mean ± SEM. Differences with p < 0.05
were considered as significant.
Results
NO generation was assessed 0.5 and 7 hours after the
induction of the inflammatory reaction. According to
previous studies (23) this production correlated to the
activation of constitutive and inducible NO synthases
respectively.
In a first series of experiments, bisthiouronium salts at
a dose of 5 X 10~5 mol/1 showed a similar inhibiting
effect to that exerted by the same dose of the reference
compound (2-methyl-2-thiopseudourea sulphate). This
dose was chosen in accordance to previous studies (23)
that demonstrated activity of this reference compound.
S,S'-(octane-l,8-diyl) bisisothiouronium dibromide
(compound I) was the major effective compound at 0.5 h
and S,S'-(nonane-l,9-diyl) bisisothiouronium dibromide
(compound II) at 7 h.
These results led us to examine the effect exerted by
these compounds compared to the reference compound
in a concentration range varying from 5 X 10 6 mol/1
and up to 10~4 mol/1 after the induction of pleurisy by
carrageenan λ. Similar results were obtained with the
three compounds at 0.5 h for the constitutive NO syn-
thase (fig. 3). The inhibiting effect was most striking on
nitrite generation measured 7 hours after the beginning
of the inflammatory reaction and reflecting the inducible
NO synthase stimulation. The dose of 5 X 10~5 mol/1
was the most effective for compound I. Compound II
seemed to be a more potent inhibitor than compound I
at 7 h, and quite similar to the reference compound at
the three doses tested (fig. 4).
Figure 5 shows the effects produced by the bisguanidi-
nium compounds (compounds III, IV, V), compound VI
and the reference compound at 0.5 and 7 h after the in-
duction of pleurisy. Results were significantly different
from controls at 0.5 h, only with the N,N'(heptane-1,7-
diyl) bisguanidinium dinitrate (compound IV) and N,N'-
bis (3-guanidinopropyl) piperazine dinitrate (compound
VI). At 7 h, all the results were significantly different
from controls, with a major effect observed with com-
pound IV and the reference compound.
Discussion
These bisisothiouronium and bisguanidinium salts de-
monstrated the inhibiting effect on NO generation in the
course of carrageenan-induced pleurisy, as well as 2-
methyl-2-thiopseudourea sulphate previously studied in
vitro by Southan et al. (16). Their activity is most signif-
icant against inducible rather than constitutive NO syn-
thases. However, the specificity of the compounds in
ί
I
<vyI
5 χ 10 * mol/1
,R I II
5 χ 10 "S mol/1 10 ·" mol/1
Fig. 3 Nitrite production (x ± S. E. M.) in the pleural cavity 0.5
hour after injection of 0.1 ml of carrageenan λ (10 g/1).
In vivo effects of various concentrations (5 X 10~6 — 1 X 10~4
mol/1) of 2-methyl-2-thiopseudourea sulphate (reference: R), S,S'-
(octane-l,8-diyl)bisisothiouronium (compound I), S,S'-(nonane-
l,9-diyl)bisisothiouronium (compound II).
C: controls. Number of animals included in each group η = 6.
* ρ < 0.05
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relation to the various isoforms of NO synthases varies
from one compound to another, but without a strict cor-
5x10° mol/1 10 "* mol/1
Fig. 4 Nitrite production (x ± S. E. M.) in the pleural cavity 7
hours after injection of 0.1 ml of carrageenan λ (10 g/l).
In vivo effects of various concentrations (5 X 10~6 — 1 X 10~4
mol/1) of R, compounds I and II.
n = 6. C: controls.
* p < 0.05, ** p < 0.01, *** p < 0.001
200-
3 100-
Fig. 5 Nitrite production (x ± S. E. M.) in the pleural cavity
0.5 Eland 7 W hours after injection of 0.1 ml of carrageenan λ (10
g/l). C: controls.
In vivo effects of 5 X 10~5 mol/1 of 2-methyl-2-thiopseudourea
sulphate and
N,N'-(hexane-l,6-diyl) bisguanidinium dinitrate (compound III),
N,N'-(heptane-l,7-diyl) bisguanidinium dinitrate (compound IV),
N,N'-(octane-l,8-diyl) bisguanidinium dinitrate (compound V), and
Ν,Ν'-bis (3-guanidinopropyl) piperazine dinitrate (compound VI).
n = 6. * p < 0.05, ** p < 0.01
relation to the chain length and to the dose. No clear
reason was found for the lack of dose-response relation-
ship, even for the reference compound. In previous ex-
periments, we have determined that 5 X 10~5 mol/1 of
2-methyl-2-thiopseudourea sulphate was sufficient for
the inhibition of NO synthases, which was never com-
plete even after administration of higher doses. Similar
phenomenon could be observed with the bisthiouronium
and bisguanidinium salts.
Garvey et al. (15) measured the apparent Kj values
for inducible and constitutive NO synthases using vari-
ous non-amino acid isothioureas. For the S-methyliso-
thiourea, the Kj values obtained by measuring percent
inhibition with at least three concentrations of the
inhibitor for inducible, constitutive endothelial and
neuronal NO synthases were 0.12, 0.2 and 0.16 μπιοΐ/ΐ
respectively. Some elements of the straight chain bis-
isothiourea showed moderate anti-NO synthase activi-
ties (15). S,S'-(ethane-l,2-diyl) bisisothiouronium and
S,S'-(heptane-l,7-diyl) bisisothiouronium exhibit the
smallest values of Kj (1.4 and 0.8 μιηοΐ/l) for the
inducible NO synthase. Extension of the central chain
R decreased the potency by increasing Kj values for
inducible NO synthase (up to 40 μηιοΐ/ΐ for the
S,S'(butane-l,4-diyl) bisisothiouronium). Consequently,
S,S'-(propane-l,3-diyl) bisisothiouronium and S,S'-(bu-
tane-l,4-diyl) bisisothiouronium compounds are clearly
not inhibitors. Unfortunately, compound II was not
investigated by Garvey et al. (15) and we could not
establish any relationship between their in vitro data
and our in vivo results.
The potential therapeutic role of NO synthase inhibitors
depends on the importance of NO release in pathological
situations (24). The full therapeutic potential will be de-
fined when NO protective functions are maintained and
when only over-production (with potential proinflamma-
tory properties) is decreased. Actually, potential thera-
peutic application of agents that modulate NO is emerg-
ing for the treatment of inflammatory disease, pulmo-
nary hypertension, radioresistance of tumour cells, sep-
tic shock and vascular restenosis following angioplasty
(25).
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